BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report

Benjamin N. Ostendorf; Hendrik Nogai; Claudia D. Baldus; Thomas Burmeister; Renate Arnold

JOURNAL

Biomarker Insights

Journal Analytics

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report

Submit a Paper

Benjamin N. Ostendorf, Hendrik Nogai, Claudia D. Baldus, Thomas Burmeister, and Renate Arnold

Biomarker Insights 2015:Suppl. 3 25-28

Case Report

Published on 30 Aug 2015

DOI: 10.4137/BMI.S22279

Further metadata provided in PDF

Download Article PDF

Sign up for email alerts to receive notifications of new articles published in Biomarker Insights

Abstract and Sharing
Article Metrics
Discuss

Abstract

The management of patients with chronic myeloid leukemia (CML) in advanced phases is challenging and requires the consideration of different treatment approaches, including targeted therapy with tyrosine kinase inhibitors, cytotoxic chemotherapy, and allogeneic stem cell transplantation. Here, we present the case of a patient with CML in mixed phenotype blast phase illustrating the integration of these strategies and demonstrating the need for close monitoring of treatment response in order to individually adjust treatment regimens.

Downloads

PDF (401.70 KB PDF FORMAT)

RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation (BIBDESK, LATEX)

What Your Colleagues Say About Biomarker Insights

I would like to extend my gratitude for creating the next generation of a scientific journal -- the science journal of tomorrow. The entire process bespoke of exceptional efficiency, celerity, professionalism, competency, and service.

Dr Jason B. Nikas (Medical School University of Minnesota, Minneapolis, MN, USA)

More Testimonials